Antidepressants and psilocybin.
44 records in this group. 20 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-14Antidepressants act on serotonin in different ways, and the published data differ with them. In an online survey, reports from people taking SSRIs or SNRIs described weaker-than-expected psilocybin effects more often than reports from people taking bupropion, which does not act directly on serotonin (47–55% vs 29%; Gukasyan 2023). Drugs that block 5-HT2A, the serotonin receptor psilocybin acts on, such as trazodone and mirtazapine, are expected to blunt its effects (Bonson 1996; Halman 2024).
With LSD, long-term tricyclic use intensified the response, while long-term use of phenelzine, an MAO inhibitor, nearly abolished it in 2 people (Bonson & Murphy 1996). One case report describes a hypertensive emergency after psilocybin mushrooms were taken with tranylcypromine, another MAO inhibitor, and extended-release dextroamphetamine-amphetamine; the authors attributed it to phenylethylamine in the mushrooms (Barnett 2024). In a small open-label trial of inhaled DMT that was not designed to compare groups, participants taking antidepressants had adverse events similar to those not taking them (Falchi-Carvalho 2025, as summarized in Tap 2025).
Stopping an antidepressant, especially suddenly, can cause withdrawal (discontinuation) symptoms or a return of depression (Zoloft prescribing information). Most psilocybin trials required stopping antidepressants before enrollment; one gave psilocybin alongside a continued SSRI (Tap 2025; Goodwin 2023). Later analyses of trial data differ on whether stopping changes the response (Erritzoe 2024; Marwood 2024).
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
- Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
- Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
- Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
- Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
- Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903.
- Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
- Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
- Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
- Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
- Zoloft (sertraline) prescribing information, sections 2 and 14 (DailyMed)
Also searched as antidepressant · depression medication · depression medicine · anti-depressant
01 What the evidence covers
Best evidence available per medication| 2 | Controlled trial |
| 5 | Open-label trial |
| 6 | Case reports Case reports or online surveys |
| 7 | Other psychedelic Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text |
| 24 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZPsychotropics
It may slightly change psilocybin's effects but does not block the receptor psilocybin works through. Also, its label warns of liver damage.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
Not studied with psilocybin; related drugs strengthened LSD's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression, including depression with anxiety or agitation
It blocks the receptor psilocybin works through, so it may weaken psilocybin, though related drugs strengthened LSD's effects.
CO: unsettled · OR: not mentioned in rule · NM: rules not final
Psychotropics
Not studied with psilocybin. Also, the infusion causes sedation and loss of consciousness, and the product is no longer marketed.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Bupropion · Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XLEvidence: Case reports
Depression (major depressive disorder); Seasonal affective disorder (prevention of seasonal depression; Wellbutrin XL, Aplenzin)
In a survey, bupropion takers less often reported weaker psilocybin effects than SSRI or SNRI takers. Also, it raises seizure risk and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder)
SSRIs often weakened psilocybin's effects in real-world reports; one trial found effects largely kept. Serotonin syndrome is unlikely, not impossible. Stopping suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Obsessive-compulsive disorder (OCD)
It may weaken psilocybin, yet 5 people on it or related drugs had stronger LSD responses. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
Its effect on psilocybin is unknown; with LSD, all 5 people on such antidepressants had stronger responses. Also, it raises blood pressure and heart rate.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (depression) in adults
It is expected to weaken psilocybin and may add to its blood pressure rise; serotonin syndrome is considered unlikely, though not impossible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (MDD) in adults; Agitation from Alzheimer's dementia
Its dextromethorphan boosts serotonin and causes dissociation, which may add to psilocybin's effects. Also, bupropion can make seizures more likely and raise blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
With LSD, long-term tricyclic use strengthened responses, so it may strengthen psilocybin (not studied). Also, it carries heart-rhythm and seizure risks.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression; Anxiety
In theory it blunts psilocybin, but related tricyclics strengthened LSD responses. Also, it sedates and affects heart rhythm; 3–6 mg acts mainly as an antihistamine.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Generalized anxiety disorder
In one case, psilocybin with duloxetine was well tolerated except mild headache; blood pressure rose. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Generalized anxiety disorder
In one controlled study, escitalopram kept psilocybin's positive mood effects and reduced anxiety and blood pressure rises. Stopping it suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Treatment-resistant depression in adults; Depressive symptoms in adults with major depression and acute suicidal thoughts or behavior
Not studied with psilocybin; it causes dissociation and raises blood pressure, so added effects are possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)
Antidepressants like this often made psilocybin feel weaker in real-world reports, and fluoxetine lingers for weeks. Stopping it suddenly after regular use can cause relapse.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Obsessive-compulsive disorder (OCD)
SSRIs often made psilocybin feel weaker in real-world reports; fluvoxamine may also slow how the body clears psilocybin.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (MDD) in adults
Like buspirone, which reduced psilocybin's visual effects, it activates a serotonin receptor, so it is expected to dampen those effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression; Bedwetting in children (short-term add-on)
Its effect on psilocybin is unclear; with LSD, it or similar drugs increased the response in all 5 people interviewed.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
It reduced LSD's effects in a small study; it is unstudied with psilocybin, and blood pressure changes with the combination are possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (MDD) in adults
It is expected to make psilocybin feel weaker, as SNRIs did in a survey; its heart rate and blood pressure rise may add to psilocybin's.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
In a small LSD study, related tricyclics increased the response, so it may strengthen psilocybin. Also, it can affect heart rhythm and lower seizure threshold.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder and dysthymia); Anxiety that comes with depression
Related antidepressants increased the LSD response, so psilocybin's effects may be stronger. Also, it can make seizures more likely and affect heart rhythm.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Also, it lowers seizure threshold and can trigger hypomania in bipolar illness.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Fibromyalgia
In a survey, people on related drugs reported weaker psilocybin effects, so it is expected to weaken psilocybin and may add to its heart-rate rise.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
In people, related drugs weakened psychedelic effects and raised psilocybin's blood pressure effect, so it is expected to do the same.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- NefazodoneEvidence: No psilocybin data
Depression
It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Also, it can cause serious, sometimes fatal, liver injury.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
In one case, psilocybin had no noticeable effect when taken with nortriptyline plus phenelzine. Also, it can affect heart rhythm and seizure threshold.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Bipolar depression (bipolar I); Treatment-resistant depression
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Depression; Obsessive-compulsive disorder (OCD)
SSRIs like paroxetine often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (particularly atypical depression)
Its label contraindicates use with serotonergic drugs, a class that includes psilocybin; in one case, psilocybin mushrooms had no noticeable effect.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
Related tricyclic drugs increased LSD's effects, so it is expected to intensify psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
Its rise in blood pressure and heart rate may add to psilocybin's; it is not expected to weaken psilocybin.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease (add-on to levodopa/carbidopa); Major depressive disorder in adults (Emsam patch)
Not studied with psilocybin; usual oral doses mainly block one enzyme (MAO-B), but the patch or higher doses may raise psilocybin levels and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)
SSRIs like sertraline often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Anxiety (promoted; not FDA-approved); Depression (promoted; not FDA-approved)
Not studied with psilocybin; its serotonin effect is unclear. Also, it acts on opioid receptors, with misuse and dependence potential.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression in adults not responding to other antidepressants
Its label contraindicates use with serotonergic drugs, a class that includes psilocybin; in one small 1968 study, it increased psilocybin's blood pressure rise.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder)
In one case, nightly trazodone blocked psilocybin's psychedelic effects; it blocks the receptor psilocybin works through. Also, it can affect heart rhythm and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
In lab studies it binds strongly to psilocybin's receptor, so it may weaken psilocybin. Also, it can affect heart rhythm and seizure risk.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Generalized anxiety disorder (GAD; extended-release)
It is expected to make psilocybin feel weaker, as SSRIs do, and higher doses may add to psilocybin's blood pressure rise.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (adults)
It acts on serotonin and may make psilocybin feel weaker, as SSRIs do. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (adults)
In one case, psilocybin during vortioxetine (with duloxetine) was well tolerated with a modest blood pressure rise. Related antidepressants were linked to weaker psilocybin effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Postpartum depression (adults)
Its sedation may add to psilocybin's effects (not studied). Also, its label warns of impaired driving for at least 12 hours after each dose.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 41 | Psychiatric reactions |
| 33 | Serotonergic |
| 33 | Withdrawal or rebound if stopped abruptly |
| 31 | Lowers seizure threshold or carries seizure risk |
| 21 | Dehydration or electrolyte risk |
| 20 | Lowers blood pressure or causes orthostasis |
| 20 | QT-prolonging |
| 20 | Raises blood pressure or heart rate |
| 18 | Sedating or CNS depressant |
| 13 | Anticholinergic |
| 8 | Blocks 5-HT2A (may blunt effects) |
| 5 | Liver injury |
| 5 | MAO inhibition |
| 2 | Dissociative (NMDA antagonist) |
| 1 | Hypoglycemia risk |
| 1 | Opioid |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governs1 of 44 named by a provision. 1 unsettled.
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” without defining the term or limiting it by indication, so whether it covers this medication is unsettled; the regulator has not addressed this. Amoxapine is an antidepressant approved for depression, but it and its metabolites block dopamine D2 receptors, as antipsychotics do, and its label describes neuroleptic malignant syndrome and tardive dyskinesia. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 42 of the 44 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Tricyclic antidepressants11 shared
- SSRI antidepressants7 shared
- MAO inhibitors5 shared
- SNRI antidepressants5 shared
- Sleep medications3 shared
Records reviewed 2026-10-14 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z